title: [Pertuzumab and solid tumors: perspectives].
abstract: Over the past decade, trastuzumab was the only available monoclonal anti-HER2 antibody for the treatment of HER2 positive breast and gastric cancer. Recently, pertuzumab added to docetaxel and trastuzumab showed dramatic overall survival improvement in first line treatment of HER2 positive metastatic breast cancer. Pertuzumab is the first approved monoclonal antibody in a new class of drugs called dimerization inhibitors. This agent was also approved in association with trastuzumab for neoadjuvant HER2-positive breast cancer treatment. However, pertuzumab development was not confined to breast cancer and in the present review, we will focus on biological rational, preclinical data and clinical trial results of pertuzumab in solid tumors excluding breast cancer.
authors.affiliation: Hôpital de Hautepierre, Hôpitaux universitaire de Strasbourg, Département d'oncologie et hématologie médicale, 1, avenue Molière, BP 49, 67200 Strasbourg, France.
authors.forename: Philippe
authors.initials: P
authors.lastname: Barthélémy
authors.affiliation: Hôpital de Hautepierre, Hôpitaux universitaire de Strasbourg, Département d'oncologie et hématologie médicale, 1, avenue Molière, BP 49, 67200 Strasbourg, France.
authors.forename: Julie
authors.initials: J
authors.lastname: Leblanc
authors.affiliation: Hôpital de Hautepierre, Hôpitaux universitaire de Strasbourg, Département d'oncologie et hématologie médicale, 1, avenue Molière, BP 49, 67200 Strasbourg, France.
authors.forename: Frédérique
authors.initials: F
authors.lastname: Wendling
authors.affiliation: Hôpitaux universitaire de Strasbourg, Département d'anatomopathologie, 67091 Strasbourg, France.
authors.forename: Marie-Pierre
authors.initials: MP
authors.lastname: Wissler
authors.affiliation: Hôpital de Hautepierre, Hôpitaux universitaire de Strasbourg, Département d'oncologie et hématologie médicale, 1, avenue Molière, BP 49, 67200 Strasbourg, France.
authors.forename: Jean-Pierre
authors.initials: JP
authors.lastname: Bergerat
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy; D003110:Colonic Neoplasms / Q000188:drug therapy; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy; D008297:Male; D009369:Neoplasms / Q000188:drug therapy*; D010051:Ovarian Neoplasms / Q000188:drug therapy; D011471:Prostatic Neoplasms / Q000188:drug therapy; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000037:antagonists & inhibitors*; D013274:Stomach Neoplasms / Q000188:drug therapy
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D018719:Erb-b2 Receptor Tyrosine Kinases; C485206:pertuzumab
keywords: cancer; colon; gastric; ovary; pertuzumab; prostate